The damage caused by cirrhosis can’t be undone, however, if the condition is diagnosed early and the underlying cause is ...
Liver biomarkers at baseline in addition to changes during follow-up are associated with cirrhosis and HCC in HDV.
Patient population for the NAVIGATE trial is based on non-invasive tests and clinical criteria utilizing latest treatment guidelines for portal ...
Lipocine Inc. , a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced the publication and discussion of a ...
Galectin Therapeutics (GALT) announced the presentation of three posters on the ongoing NAVIGATE trial in patients with MASH cirrhosis and portal hypertension at the American Association for the Study ...
PORTAL vein thrombosis (PVT) is a common and serious complication in patients with liver cirrhosis. It can lead to obstructed ...
Cirrhosis is a progressive liver condition that often remains hidden in its early stages. The disease, marked by irreversible ...
No new safety findings were observed. The most common treatment-emergent adverse events (>10 percent) occurring more ...